AstraZeneca's Imfinzi Immunotherapy Gets U.S. FDA Approval for Endometrial Cancer
By Elena Vardon
AstraZeneca said the U.S. Food and Drug Administration approved the use of its Imfinzi immunotherapy along with chemotherapy for endometrial cancer.
The British-Swedish pharma giant said Monday that it received approval in the U.S. for the drug--in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy--to be used to treat adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient.
The FDA gave the group the green light based on the results of its DUO-E Phase 3 trial, which showed Imfinzi reduced the risk of disease progression or death by 58% against chemotherapy alone, AstraZeneca said.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
June 17, 2024 02:29 ET (06:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued